Product logins

Find logins to all Clarivate products below.


In 2023, sales of insulins at the ex-manufacturer price level exceeded $18 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3 billion. Throughout our 2023-2033 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi as well as Amgen / Daiichi Sankyo’s Prolia / Pralia will face increasing competition from biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecast for key reference brand insulins and antiresorptive analogues and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Rare Diseases and Orphan Drugs – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…